Literature DB >> 11921275

Unique balanced chromosome abnormalities in treatment-related myelodysplastic syndromes and acute myeloid leukemia: report from an international workshop.

Harold J Olney1, Felix Mitelman, Bertil Johansson, Krzysztof Mrózek, Roland Berger, Janet D Rowley.   

Abstract

A total of 123 balanced rearrangements, including 26 occurring as a sole anomaly, not known to be recurrent in myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) prior to the Workshop, were ascertained retrospectively from 104 patients with treatment-related MDS/AML (t-MDS/t-AML). Thirteen of the aberrations were reported previously in single cases and hence may be classified as recurrent as a result of the Workshop. Patients with Unique aberrations had complex karyotypes more often (P < 0.001 for all pairwise comparisons) than did other Workshop subgroups, with 72% having 3 or more aberrations. Among 85 cases with secondary chromosomal abnormalities, -5, -7, del(5q), and del(7q) were observed in 76%, which is significantly higher (P < or = 0.007 for all pairwise comparisons) than the frequencies found in the Workshop subgroups of patients with previously known recurring aberrations. The chromosome bands most often involved in balanced aberrations were 1p36 and 3q26-27. Treatment exposure was significantly different (less topoisomerase II inhibitor exposure, more radiotherapy-only exposure) than for patients with 11q23 (P < 0.001 and P = 0.002, respectively) and 21q22 (P = 0.007 and P = 0.002, respectively) abnormalities. The median time from the first toxic exposure to secondary disease, 59 months, was significantly longer (P < or = 0.016 for all significant pairwise comparisons) than the median latency of all other patients except those in the Rare subgroup, and the median survival time, 7 months, was significantly shorter than for patients in the 21q22, inv(16), and t(15;17) subgroups (P < or = 0.002 for all pairwise comparisons), but similar to patients in the 11q23 and Rare subgroups. In contrast to known recurring abnormalities, significantly more patients (61%, all P < 0.001) presented with t-MDS, with over one-third of these patients progressing to t-AML. Thus, this group of patients appears to be more similar to the typical t-MDS/t-AML patients, with complex karyotypes as well as chromosome 5 and 7 abnormalities, than to those with recurrent balanced rearrangements. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 11921275     DOI: 10.1002/gcc.10045

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  10 in total

Review 1.  Therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplantation in lymphoma patients.

Authors:  Mojtaba Akhtari; Vijaya Raj Bhatt; Pavan Kumar Tandra; Jairam Krishnamurthy; Heidi Horstman; Amy Dreessen; Pei Xian Chen; James O Armitage
Journal:  Cancer Biol Ther       Date:  2013-10-18       Impact factor: 4.742

2.  Therapy-related myelodysplastic syndrome: a case study.

Authors:  Masahiro Manabe; Katsuya Wada; Dai Momose; Yasuyoshi Sugano; Masayuki Hino; Takahisa Yamane; Eiwa Ishida; Ki-Ryang Koh
Journal:  Am J Blood Res       Date:  2015-12-25

Review 3.  Causes of oncogenic chromosomal translocation.

Authors:  Peter D Aplan
Journal:  Trends Genet       Date:  2005-10-28       Impact factor: 11.639

4.  Clinical and pathologic features of secondary acute promyelocytic leukemia.

Authors:  Amy S Duffield; Joseph Aoki; Mark Levis; Kathleen Cowan; Christopher D Gocke; Kathleen H Burns; Michael J Borowitz; Milena Vuica-Ross
Journal:  Am J Clin Pathol       Date:  2012-03       Impact factor: 2.493

5.  Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy.

Authors:  Farshid Dayyani; Hagop Kantarjian; Susan O'Brien; Sherry Pierce; Dan Jones; Stefan Faderl; Guillermo Garcia-Manero; Jorge Cortes; Farhad Ravandi
Journal:  Cancer       Date:  2010-08-27       Impact factor: 6.860

6.  New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461.

Authors:  Alison Walker; Krzysztof Mrózek; Jessica Kohlschmidt; Kathleen W Rao; Mark J Pettenati; Lisa J Sterling; Guido Marcucci; Andrew J Carroll; Clara D Bloomfield
Journal:  Genes Chromosomes Cancer       Date:  2012-12-10       Impact factor: 5.006

Review 7.  Therapy-related myeloid leukemia.

Authors:  Lucy A Godley; Richard A Larson
Journal:  Semin Oncol       Date:  2008-08       Impact factor: 4.929

8.  Effect of therapy-related acute myeloid leukemia on the outcome of patients with acute myeloid leukemia.

Authors:  Ana Espírito ESPíRITO Santo; Sérgio Chacim; Isabel Ferreira; Luís Leite; Claudia Moreira; Dulcineia Pereira; Margarida Dantas Dantas Brito; Marta Nunes; Nelson Domingues; Isabel Oliveira; Ilídia Moreira; Angelo Martins; Luísa Viterbo; José Mário Mariz; Rui Medeiros
Journal:  Oncol Lett       Date:  2016-05-17       Impact factor: 2.967

9.  Therapy-related Acute Myeloid Leukemia after the Long-term Administration of Low-dose Etoposide for Chronic-type Adult T-cell Leukemia-lymphoma: A Case Report and Literature Review.

Authors:  Naoki Shimada; Nobuhiro Ohno; Ryuji Tanosaki; Shigeo Fuji; Yuhko Suzuki; Koichiro Yuji; Kaoru Uchimaru; Arinobu Tojo
Journal:  Intern Med       Date:  2017-07-15       Impact factor: 1.271

Review 10.  Therapy-related myeloid neoplasms: clinical perspectives.

Authors:  Luana Fianchi; Marianna Criscuolo; Emiliano Fabiani; Giulia Falconi; Alessio Maria Edoardo Maraglino; Maria Teresa Voso; Livio Pagano
Journal:  Onco Targets Ther       Date:  2018-09-17       Impact factor: 4.147

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.